# Sirolimus for the Treatment of Hyperinsulinism

> **NCT02524639** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Children's Hospital of Philadelphia**

## Conditions studied

- Hyperinsulinism

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02524639
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-08-12
- **Primary completion:** 2018-05-29
- **Final completion:** 2018-05-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to strict inclusion and exclusion criteria no subjects were enrolled
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02524639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02524639, "Sirolimus for the Treatment of Hyperinsulinism". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT02524639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*